Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas Dec 29, 2020
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases Dec 17, 2020
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference Dec 3, 2020
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML Nov 19, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020 Nov 13, 2020
Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event Oct 27, 2020
Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors Oct 21, 2020
